VERU INC. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
VERU INC. (VERU) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 260.08 thousand shares for the 12-month period ending 2016-09-30, per its 10-K filed 2018-01-02.
Discontinued › Notes
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2018-01-02
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2016-06-30 was 398.18K shares, a 80.55% increase year-over-year.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2016-03-31 was 406.66K shares, a 57.12% increase year-over-year.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2015-12-31 was 360.57K shares, a 30.57% increase year-over-year.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2015-06-30 was 220.53K shares, a 31.89% decline year-over-year.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2016 was 260.08K shares, a 32.40% decline from fiscal 2015.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2015 was 384.72K shares, a 12.21% increase from fiscal 2014.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2014 was 342.86K shares, a 2.00% decline from fiscal 2013.
- VERU INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2013 was 349.87K shares, a 71.77% decline from fiscal 2012.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 6 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|---|
| 2016-09-30 | 260.08K shares 10-K · filed 2018-01-02 | |||
| 2016-06-30 | 398.18K shares 10-Q · filed 2017-08-09 | 411.30K shares 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | 406.66K shares 10-Q · filed 2017-05-10 | 403.98K shares 10-Q · filed 2017-05-10 | ||
| 2015-12-31 | 360.57K shares 10-Q · filed 2017-02-09 | |||
| 2015-09-30 | 384.72K shares 10-K · filed 2018-01-02 | |||
| 2015-06-30 | 220.53K shares 10-Q · filed 2016-07-28 | 234.47K shares 10-Q · filed 2016-07-28 | ||
| 2015-03-31 | 258.82K shares 10-Q · filed 2016-04-28 | 262.78K shares 10-Q · filed 2016-04-28 | ||
| 2014-12-31 | 276.15K shares 10-Q · filed 2016-02-02 | |||
| 2014-09-30 | 342.86K shares 10-K · filed 2016-12-12 | |||
| 2014-06-30 | 323.78K shares 10-Q · filed 2015-07-30 | 337.54K shares 10-Q · filed 2015-07-30 | ||
| 2013-09-30 | 349.87K shares 10-K · filed 2015-12-02 | |||
| 2013-03-31 | 364.35K shares 10-Q · filed 2013-05-02 | 362.96K shares 10-Q · filed 2013-05-02 | ||
| 2012-12-31 | 361.54K shares 10-Q · filed 2013-01-30 | |||
| 2012-09-30 | 1.24M shares 10-K · filed 2012-12-04 | |||
| 2012-06-30 | 1.55M shares 10-Q · filed 2012-07-31 | 1.49M shares 10-Q · filed 2012-07-31 | ||
| 2012-03-31 | 1.49M shares 10-Q · filed 2013-05-02 | 1.45M shares 10-Q · filed 2013-05-02 | ||
| 2011-12-31 | 1.40M shares 10-Q · filed 2013-01-30 | |||
| 2011-09-30 | 1.68M shares 10-K · filed 2012-12-04 | |||
| 2011-06-30 | 1.67M shares 10-Q · filed 2012-07-31 | 1.70M shares 10-Q · filed 2012-07-31 | ||
| 2010-09-30 | 1.56M shares 10-K · filed 2012-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |